Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts by unknown
ACCUMULATION  OF  DIABETIC  RAT  PERIPHERAL  NERVE 
MYELIN  BY  MACROPHAGES  INCREASES  WITH  THE 
PRESENCE  OF  ADVANCED  GLYCOSYLATION 
ENDPRODUCTS 
By  HELEN  VLASSARA,  MICHAEL  BROWNLEE,  AND  ANTHONY  CERAMI 
From the Laboratory of Medical Biochemistry,  The Rockefeller University, 
New York, New York 10021 
Diabetic peripheral neuropathy, the most common long-term complication of 
diabetes mellitus, is characterized morphologically by segmental demyelination. 
The extent and degree of this pathological change correlates with the severity 
and duration of hyperglycemia (1). 
We have previously shown that increased nonenzymatic glycosylation (NEG), 1 
a process known to occur in a number of body proteins (2-4), occurs in peripheral 
and central nervous tissue of diabetic humans and animals (5).  More recently, 
we have demonstrated that most of the NEG occurs specifically on the structurally 
and quantitatively major myelin proteins: PO-protein in peripheral nerve myelin 
and  proteolipid  and  basic  protein  in  central  nervous system myelin (6).  The 
pathophysiologic mechanism by which this biochemical alteration might lead to 
myelin breakdown and removal is not as yet understood. 
Short-term  incubation  of proteins  with  glucose results  in  the  formation of 
ketoamine adducts (Amadori product) with protein amino groups. These adducts 
are reversible and reach equilibrium after several weeks. In addition to detaching 
from the protein, these glyco-adducts can undergo very slowly further rearrange- 
ments, dehydrations, and reactions to form a number of advanced glycosylation 
end-products (AGE), which are characteristically yellow-brown fluorescent chro- 
mophores that  can cross-link proteins.  In contrast to  the initial  adduct, these 
AGE adducts are irreversible and can therefore accumulate on long-lived proteins 
such as collagen, lens crystallins, basement membrane, and myelin (7). 
The  recent isolation  of and  assignment  of a  structure  to  an  AGE protein 
adduct  has  provided  crucial  information  about  how  two  NEG  proteins  can 
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condense to form a specific yellow fluorescent product, 2-furoyl-4(5)-(2-furanyl)- 
1H-imidazole (FFI) (8). 
We  postulated  that  perhaps  more  extensive  modification of myelin protein 
structure by these AGE adducts might be necessary to stimulate mobilization of 
tissue macrophages against myelin. Such a stimulus could induce myelin protein 
uptake  and  degradation  through  receptor-mediated  phagocytosis,  proteolytic 
enzyme secretion (9), or complement activation in the absence of myelin-specific 
antibodies (10). 
In  this  study,  we  report  that  AGE-myelin  is  modified  so  that  it  becomes 
recognizable by macrophages. We have demonstrated that elicited macrophages 
accumulate ~2~I-labeled  peripheral myelin that has been extensively glycosylated 
in vitro and in vivo. This response correlates well with the extent and duration 
of myelin glycosylation. 
Materials and Methods 
Myelin Preparation from Normal and Diabetic Rats.  Peripheral myelin was isolated from 
sciatic nerves of alloxan-induced diabetic (mean blood glucose above 250 mg/dl), and age- 
matched  normal  Sprague  Dawley rats  by  standard  ultracentrifugation procedures  as 
described previously (6). Myelin was isolated from young animals with early diabetes (4- 
5 wk) and from older rats with diabetes of long duration (1.5-2.0  years).  Aliquots of 
myelin (10/zg) were subjected to sodium dodecyl sulfate polyacrylamide  gel electrophoresis 
(SDS-PAGE) for verification of preparation purity (11). The pattern of protein bands 
from all diabetic myelin samples  was identical to that observed with identically treated 
normal myelin. 
In Vitro Glycosylation of Peripheral  Nerve Myelin.  Normal peripheral myelin was incu- 
bated  separately  in  50  mM  glucose,  50  mM  glucose-6-phosphate  (G-6-P)  or  0.!  M 
phosphate-buffered saline (PBS) at 37 °C for 8 wk, in the presence of protease inhibitors 
(PMSF  1.5 mM, EDTA 0.5 mM) and antibiotics (penicillin  100 U/ml, gentamicin 40 mg/ 
ml). 
In  order  to determine the  amount of nonenzymatic glycosylation present  in  these 
preparations,  an  affinity chromatography system  that  selectively retains  glycosylated 
adducts was utilized. Portions of myelin preparations were first subjected to reduction 
with NaB3H4 (specific activity 80 uCi//tmol) and then chromatographed on immobilized 
m-aminophenyl-boronic acid as described previously (12). Glycosylated myelin averaged 
12,000  + 2,000 cpm/t~mol of total amino acid, while control samples averaged only 2,000 
4- 300 cpm//~mol of total amino acid. Aliquots of myelin (10/~g) were subjected to SDS- 
PAGE for verification of preparation purity (11). The pattern of protein bands from all 
glycosylated myelin samples was identical to that observed with identically treated normal 
myelin. It should be noted that only Amadori products are detected by current methods 
used to  quantitate  the  extent of nonenzymatic glycosylation. At present,  there  is  no 
specific quantitative assay for AGE proteins (13). However, brown pigments were observed 
in the in vitro and the long-term diabetic samples. 
1251-lodination of Myelin Proteins.  Portions of each myelin preparation were radioiodi- 
nated by the Iodogen method of Fraker and Speck (14). Samples were dialyzed against a 
1,000-fold excess  of 0.01  M  PBS  (pH  7.0)  until >95%  of the  radioactivity was TCA 
precipitable. Protein concentration was determined by the Bradford method (15). Specific 
activity varied from 45,000-50,000 cpm//zg. 
Isolation of Mouse Peritoneal Macrophages.  Female NCS mice (25-30 g) were obtained 
from the LARC facility of The Rockefeller University. Resident peritoneal macrophages 
were harvested in PBS as described by Edelson and Cohn (16). Inflammatory macrophages 
were obtained 6 d after the intraperitoneal injection of 3.0 ml of Brewer's thioglycolate 
broth (Difco Inc., Detroit, MI). The fluid from 15-20 mice (6.8  x  106 cells/mouse) was 
pooled and centrifuged at  500 g  for  10  min, washed once with 20  ml of Dulbecco's VLASSARA ET  AL.  199 
Modified Eagle's Medium (Gibco  Laboratories, Grand Island, NY) and resuspended in 
medium containing  10%  FBS,  penicillin (100  U/ml),  and  streptomycin (100  mg/ml). 
Aliquots were plated in Linbro plastic petri dishes (1.0 × 3.5 cm) (Linbro Scientific,  Inc., 
Hamden,  CT),  and  incubated at  37°C  in  5%  CO2  for 2  h.  After three washes  with 
medium, each well received 1.0 ml of fresh medium, containing varying amounts of 125I- 
labeled rat peripheral nerve myelin preparations. Each dish at that point contained ~60% 
of the total number of cells originally plated (4-5 ×  105 cells/well). 
Myelin Uptake and Degradation Experiments.  To evaluate the accumulation of myelin 
by macrophages as a function of time, aliquots containing 80-100 #g of normal, short- 
term diabetic, long-term diabetic, and in vitro glycosylated myelin protein were added to 
each macrophage culture dish and incubated for various periods of time.  At selected 
intervals, the culture medium was removed, cell monolayers were washed three times and 
then lysed by either addition of 1.0 ml distilled H20 or by rapid freeze-thawing. The 
lysate in  each  well  was  counted  in  a  Packard  liquid scintillation counter in  order to 
determine the amount of cell-associated  l~I-radioactivity. 
In order to establish that cell-associated  radioactivity represents internalization rather 
than surface binding of protein, the lzSI-myelin-containing  medium was removed at the 
end of a  5-h  incubation, and trypsin (Sigma  Chemical Co., St.  Louis, MO) was added 
(0.05%  final concentration) to the wells. After incubation at 37°C for 5 min, the cell 
monolayers were washed four times with media containing 20%  FBS and processed as 
described above. 
Further evidence that internalization had occurred was sought by incubating identical 
concentrations (5 to 100 #g) of AGE- and control-myelin at 37 °C and 4 °C for 4 h (I 7). 
The  specificity of the  AGE-myelin interaction  with  macrophages  was  assessed  by 
incubating 25 #g of ~2~I-AGE-myelin  with varying amounts (25 to 2,500 ug) of potentially 
competing unlabeled compounds as previously described (17). Substances evaluated were 
AGE-myelin, AGE-BSA, yeast mannan (Sigma), control myelin, and control BSA. 
To evaluate rates of cellular myelin degradation, ~SI-myelin (50 #g/well) from diabetic 
and age-matched normal tissue was incubated with cells for 6 h. The myelin-containing 
medium was removed and the  cells were  washed three times with  1.0  ml serum-free 
medium. Following this, the amount of ~25I-labeled material remaining in the cells was 
measured at 0, 2, 4, 6, and 12 h. 
In all experiments, myelin adsorption to plastic was ruled out by demonstrating that in 
control  wells  containing  ~25I-myelin alone,  radioactivity did not exceed  0.5%  of that 
observed in association with cells. 
Results 
Uptake of Myelin  Proteins  Glycosylated In  Vitro.  Resident  mouse  peritoneal 
macrophages were incubated with both normal myelin and myelin glycosylated 
in  vitro.  The  cellular  accumulation  of both  normal  and  glycosylated myelin 
samples was low and not significantly different (mean 0.4 +  0.2 #g/well). Similar 
experiments using thioglycolate-elicited macrophages instead resulted in marked 
differences in cell accumulation of radioactivity between normal and glycosylated 
myelin.  For  this  reason,  only  elicited  macrophages  were  used  in  subsequent 
studies. 
The specificity of AGE-myelin accumulation by thioglycolate-elicited macro- 
phages was assessed by experiments in which macrophages were incubated with 
125I-AGE-myelin in the presence of increasing concentrations (25-2,500  #g) of 
cold AGE-myelin, AGE-BSA,  yeast mannan,  control  myelin, and control  BSA 
(Fig.  1).  Unlabeled AGE-myelin and AGE-BSA were both effective competitors 
of 125I-AGE-myelin accumulation.  Similar experiments in  which  25  #g of l~5I- 
control myelin was incubated with increasing amounts (25-2,500 #g) of unlabeled 
control myelin showed a concentration-dependent inhibition of 125I-control mye- 200  MACROPHAGE  ACCUMULATION  OF  AGE-MYELIN 
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FIGURE  l.  Intracellular l~I-AGE-myelin  accumulation in the presence of increasing concen- 
trations of potentially competing unlabeled compounds. Substances tested were AGE-myelin 
(O), AGE-BSA (/X), yeast mannan (~), control myelin (O), and control BSA (X). Each  dish 
125  received 25 #g of  I-AGE-myelin and the indicated amounts of unlabeled competitor and 
was incubated for 5 h at 37°C. Values are expressed as percent of control. The 100% value 
was 5.9 ttg. 
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FIGURE 2.  Effect of temperature on cellular accumulation of ]2~I-AGE-myelin (b) and l~51- 
control myelin (0). Identical concentrations of each labeled ligand (25 #g to 100 ~g/ml) were 
incubated at either 37°C or 4°C. 
lin (data not shown). In contrast, neither unlabeled control nor unlabeled control 
BSA competed with 125I-AGE-myelin  accumulation. Yeast mannan also failed to 
compete. 
In these experiments 75-80%  of cell-associated radioactivity remained after 
incubation  with trypsin.  A  temperature-dependent inhibition  of cellular accu- 
mulation of radioactivity was observed when identical experiments were carried 
out at both 4°C and 37°C (Fig. 2). 
Macrophage  accumu|ation  of  ~25I-myelin  previously  incubated  in  50  mM 
glucose or G-6-P  for 8  wk at  37°C  was  compared with  the accumulation of 
myelin incubated in 0.1  M phosphate-buffered saline (PBS) for the same period 
of time. Fig. 3 displays the uptake of the various myelin preparations. Accumu- 
lation  increased in  a  linear  fashion  for the  first  6  h,  and  remained constant VLASSARA  ET  AL.  201 
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FIGURE 3.  Accumulation of l*5I-myelin by mouse peritoneal macrophages as a  function of 
time (h). Normal rat peripheral nerve myelin was previously incubated in 50 mM glucose (0) 
50 mM G-6-P (A) or PBS (O) at 37°C for 8 wk. Each well (4.0 x  105 cells) received 100 t~g of 
labeled myelin. The data are expressed as the mean of six independent measurements. 
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FIGURE 4.  Accumulation of l~5I-myelin from short-term diabetic (O) and age-matched normal 
rats (O) by mouse peritoneal macrophages as a function of time (h). Each well (4.0 x  l0  s cells) 
received  100 #g of labeled myelin. The data are expressed as the mean of six independent 
measurements. 
thereafter (up to 24 h).  Maximal rates of intracellular accumulation of G-6-P 
glycosylated myelin (mean 10.8 -+ 0.4 #g/well) and glucosyl-myelin (mean 6.4 + 
0.4 #g/well) were 10 times and 5 times greater, respectively, than myelin samples 
incubated in buffer alone (mean 1.2 +  0.2/zg/well). The difference between the 
rate observed with glucose and G-6-P probably reflects differences in the rate of 
nonenzymatic protein glycosylation, which increases significantly when G-6-P is 
substituted for glucose in equimolar concentrations (I 8). 
Uptake of Myelin Proteins  from Short- and Long-term Diabetic Animals.  Experi- 
ments comparing uptake of 195I-myelin isolated from short-term diabetic animals 
(4-6 wk) with uptake of myelin from age-matched controls showed similar low 
rates of intracellular accumulation of labeled material in both groups (normal: 
1.2  -  0.2 ~tg/well; diabetic; 2.0 -+ 0.4 #g/well) (Fig. 4). In contrast, accumulation 
of l~SI-myelin  isolated from rats  with long-term diabetes (1.5-2.0  years)  was 
three to four times greater than that of age-matched normals (normal: 2.4 _+ 0.5 202  MACROPHAGE  ACCUMULATION  OF  AGE-MYELIN 
~zg/well; diabetic: 9.0 +  0.5 ug/well) (Fig. 5) and nine times greater than that of 
the 4-6-wk old normal myelin shown in Fig. 4. 
Effect of AGE on Intracellular Myelin Degradation.  After incubating 125I-myelin 
(50 ~g/well) from both long-term diabetic and normal tissue with macrophages 
for 6  h, the myelin-containing medium was removed, the cell monolayers were 
washed  thoroughly and  fresh  medium was  added.  At  specific  time  intervals, 
trichloroacetic acid (TCA)-soluble  radioactivity in  the fresh  media and TCA- 
insoluble radioactivity within the cells were measured separately. 
Despite the several-fold greater amount of diabetic myelin accumulated within 
the cells at the end of 6 h, the relative rate of disappearance of TCA-insoluble 
myelin from  within  the cells  (Fig.  6),  and  the  rate  of appearance  of soluble 
degradation products in the fresh media (data not shown) was the same for both 
diabetic and normal after 12 h (Fig. 6). 
Discussion 
The results presented in this report show that the NEG products formed by 
long-term exposure of peripheral nerve myelin proteins to glucose in vitro and 
in vivo markedly alter the way in which myelin interacts with activated macro- 
phages.  In  this  interaction,  macrophages appear  to  specifically recognize Ad- 
vanced Glycosylation Endproducts (AGE) on myelin since AGE-BSA competes 
nearly as effectively as AGE-myelin, while neither unmodified BSA nor unmod- 
ified myelin compete. The failure of yeast mannan to interfere with macrophage 
recognition of AGE-myelin suggests that the mannose/fucose receptor does not 
mediate this process. 
Recognition of AGE-protein by macrophages is associated with endocytosis, as 
demonstrated by resistance of cell-associated radioactivity to removal by trypsin 
action, and by low-temperature inhibition of ligand accumulation in the cellular 
fraction. The rate and extent of NEG of proteins are functions of both glucose 
concentration  and  time  of exposure  to  glucose  (19).  Thus,  the  high  sugar 
concentrations used (900 mg/dl) in the in vitro glycosylation experiments resulted 
in a significant increase in myelin accumulation, while peripheral nerve myelin 
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FIGURE 5.  Accumulation of l~51-myelin from long-term diabetic (0) and age-matched normal 
rats (O) by mouse peritoneal macrophages as a function of time (h). Each well (4.0 x  105 cells) 
received  100  #g of labeled myelin. The  data  are expressed as a  mean of six  independent 
measurements. VLASSARA  ET  AL.  203 
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FIGURE 6.  Comparison  of the  disappearance  rate  of  intracellular  diabetic  (0)  and  age- 
matched normal (©) myelin, accumulated by macrophages during 6 h of incubation, The data 
are plotted on a  semilogarithmic scale and  linear regression analysis was  used to obtain tV2 
values (D =  10.4 h; N =  10.4 h) for each myelin preparation. 
from rats having diabetes for a  similar length of time (4-6  wk,  blood glucose 
range 250-350  mg/dl), was taken up by macrophages almost to the same low 
degree as  myelin  from  age-matched  normals.  Accumulation  of myelin  from 
diabetic rats exposed to similar levels of hyperglycemia for two years, however, 
was almost 9 times greater than that of myelin from young normal and 3.5 times 
more than that of myelin from age-matched controls.  These data suggest that 
short-term hyperglycemia in  vivo results  in  fewer glucose-induced alterations 
"recognizable" by macrophages than does long-term hyperglycemia. Different 
degrees of myelin accumulation by macrophages were also observed between the 
two  normal  myelin  preparations  from  rats  differing only  in  age.  This  most 
probably reflects a  similar,  although  much slower,  NEG process occurring in 
normal myelin as a function of age. 
Intracellular  myelin  accumulation  reflects an  equilibrium  between  uptake, 
degradation, and secretion by the macrophages. In order to dissect out the main 
components associated with the observed intracellular difference, the disappear- 204  MACROPHAGE  ACCUMULATION OF  AGE-MYELIN 
ance of acid-insoluble radioactivity from within the cells and the appearance of 
acid-soluble radioactivity released into the medium were monitored independ- 
ently over an extended period of time (12 h). The observed rate of intracellular 
degradation  recorded  was  very  similar  for  the  two  groups  (Fig.  6).  Thus, 
increased uptake of long-term diabetic myelin appeared to be the main contrib- 
utor to the striking difference in accumulation seen between the two groups. 
Endocytosis of myelin with advanced glycosylation is consistent with previously 
described increases in  receptor-mediated phagocytosis associated  with macro- 
phage stimulation (20). The mechanism by which this activation occurs in vivo is 
not known. 
Macrophage endocytosis of a number of covalently modified proteins appears 
to be mediated by scavenger receptors that recognize induced changes in charge 
and/or conformation (17, 21). Proteins modified using formaldehyde, glutaral- 
dehyde, malondialdehyde, acetylation, acetoacetylation, carbamylation, and mal- 
eylation have all  been shown to stimulate uptake via these scavenger receptor 
pathways (17, 22-24). 
The observations presented in this report suggest that covalent protein modi- 
fication  by  AGE  results  in  a  similar recognition and  uptake by  a  scavenger 
pathway.  Witzum et  al.  (25)  have  reported no scavenger pathway  uptake of 
glycosylated low density lipoprotein by peritoneal macrophages following short- 
term glucose incubation. However, Haberland et al. (21) have recently demon- 
strated  that  protein  uptake  by  a  scavenger receptor  does  not  occur  until  a 
threshold level of modified residues is reached (21). The differences observed 
by us between macrophage uptake of long-term and short-term diabetic myelin 
are most likely a reflection of this phenomenon. 
The interaction of maleylated albumin with its receptor has  recently been 
reported to trigger secretion of neutral proteases such as plasminogen activator 
(26).  Since  the  major  protein  components of peripheral  nervous myelin are 
particularly  susceptible  to  degradation  by  plasmin  (27),  similar  plasminogen 
activator  secretion  induced by  covalently modified myelin could lead  to  the 
segmental demyelination associated with diabetes. 
AGE-adducts attached tO long-lived proteins such as collagen or myelin have 
been shown to trap covalently plasma proteins such as  IgG leading to  in situ 
formation of immune complexes (28). This could also contribute to macrophage- 
associated destruction of diabetic tissues. Indeed, deposition of IgM and comple- 
ment (C3) has recently been shown to occur on peripheral nerves of diabetic 
patients having clinical peripheral neuropathy (29). 
The observations described in this report provide a  pathophysiological link 
between excessive myelin protein nonenzymatic glycosylation induced by hyper- 
glycemia and segmenal demyelination in diabetes.  Over long periods of time, 
diabetes can induce chemical modification of long-lived myelin proteins, which 
results in the formation of advanced glycosylation endproducts (10,  15).  For- 
mation of these irreversible products appears to modify the properties of myelin 
proteins in a way "recognizable" by macrophages, thus, potentially initiating or 
contributing to the segmental demyelination associated with diabetes and the 
normal aging of peripheral nerve. The early, more reversible steps of nonenzy- 
matic glycosylation do not appear  capable  of inducing such a  response.  The VLASSARA ET AL.  ~05 
irreversible nature of AGE adducts formed on long-lived proteins such as myelin 
suggests  that  clinical efforts at  controlling hyperglycemia in  diabetic patients 
must be initiated early in the course of the disease in order to be effective. 
Summary 
We have previously shown that increased nonenzymatic glycosylation occurs 
in peripheral nervous tissue of diabetic humans and animals, primarily on the 
PO-protein  of peripheral  never myelin. The  pathophysiologic mechanism by 
which this biochemical alteration leads to myelin breakdown and removal is not 
as yet understood. 
In the present study we show that advanced glycosylation end-product (AGE) 
adducts that form during long-term exposure of peripheral nerve myelin proteins 
to glucose in vitro and in vivo markedly alter the way in which myelin interacts 
with elicited macrophages. In this interaction, macrophages appear to specifically 
recognize AGEs on  myelin, since AGE-BSA competes nearly as effectively as 
AGE-myelin, while neither unmodified BSA nor unmodified myelin compete. 
The failure of yeast mannan to interfere with macrophage recognition of AGE- 
myelin suggests that the mannose/fucose receptor does not mediate this process. 
Recognition of AGE-protein by macrophages is associated with endocytosis, as 
demonstrated by resistance of cell-associated radioactivity to removal by trypsin 
action, and by low temperature inhibition of ligand accumulation in the cellular 
fraction. ~5I-labeled myelin that had been incubated in vitro with 50 mM glucose 
for 8 wk reached a steady state accumulation within thioglycolate-elicited mac- 
rophages  that  was  five  times  greater  than  that  of myelin incubated  without 
glucose. Similarly, myelin isolated from rats having diabetes for  1.5-2.0  years 
duration had a  steady state level that was 9  times greater than that of myelin 
from young rats, and 3.5  times greater than that of myelin from age-matched 
controls. In contrast, myelin isolated from rats having diabetes for 4-5 wk had 
the same degree of accumulation observed with myelin of age-matched normal 
rats. These data suggest that the amount of increased nonenzymatic glycosylation 
observed in  the myelin of short-term diabetic rats had not yet resulted in the 
significant accumulation of AGE-myelin present both in vitro and in the long- 
term diabetic rats. 
The disappearance of acid-insoluble radioactivity from within the cells and the 
appearance  of acid-soluble  radioactivity released into  the  medium were very 
similar for the two groups, suggesting that the striking difference in accumulation 
seen  between  normal  myelin and  AGE-myelin is  due  primarily to  increased 
uptake. 
Formation of irreversible  AGE-adducts  on  myelin appears  to  promote  the 
recognition and uptake of the modified myelin by macrophages. This interaction 
between AGE-myelin and macrophages may initiate or contribute to the segmen- 
tal demyelination associated with diabetes and the normal aging of peripheral 
nerve. 
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